Table 7.
Summary of final response status assessments by patient
| Primary diagnosis | Assigned treatment | Completed cycles of treatment | Best overall overall responsea |
|---|---|---|---|
| Renal cell carcinoma | Edotecarin + 5-FU/LV | Cycle 3 | PD |
| Pancreatic cancer | Edotecarin + 5FU/LV | Cycle 18 | SD |
| Adenocarcinoma of pancreas | Edotecarin + 5-FU/LV | Cycle 3 | PD |
| Epidermoid lung carcinoma | Edotecarin + 5-FU/LV | Cycle 3 | PD |
| 1/3 esophagus carcinoma | Edotecarin + 5-FU/LV | Cycle 9 | SD |
| Adrenal carcinoma | Edotecarin + 5-FU/LV | Cycle 3 | SD |
| Pancreatic adenocarcinoma | Edotecarin + 5-FU/LV | Cycle 3 | PD |
| Hepatocarcinoma | Edotecarin + 5-FU/LV | Cycle 12 | CR |
| Moderately differentiated adenocarcinoma duodenum | Edotecarin + 5-FU (w/bolus) +LV | Cycle 7 | SD |
| Gastric carcinoid | Edotecarin + 5-FU (w/bolus) +LV | Cycle 9 | SD |
| Ampullary cancer | Edotecarin + 5-FU (w/bolus) +LV | Cycle 6 | SD |
| Small cell neuroendocrine carcinoma liver metastases | Edotecarin + 5-FU (w/bolus) +LV | Cycle 3 | PD |
| Bronchus carcinoma | Edotecarin + 5-FU (w/bolus) +LV | Cycle 8 | SD |
| Superior pole of left kidney cancer | Edotecarin + 5-FU (w/bolus) +LV | Cycle 3 | PD |
5-FU, 5-fluorouracil; CR, complete response; LV, leucovorin; PD, progression of disease; SD, stable disease.
a
As determined by the investigator.